Compare TRTX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | MNMD |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.3M | 960.2M |
| IPO Year | 2017 | N/A |
| Metric | TRTX | MNMD |
|---|---|---|
| Price | $9.16 | $12.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $10.75 | ★ $25.78 |
| AVG Volume (30 Days) | 516.7K | ★ 1.5M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 10.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.19 | N/A |
| P/E Ratio | $14.14 | ★ N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $6.47 | $4.70 |
| 52 Week High | $9.85 | $14.43 |
| Indicator | TRTX | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 55.67 |
| Support Level | $9.01 | $12.19 |
| Resistance Level | $9.17 | $13.45 |
| Average True Range (ATR) | 0.14 | 0.70 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 87.00 | 72.07 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).